Inivata Expands Leadership Team with the Appointment of Two Senior Executives

CAMBRIDGE, England, May 8, 2015 /PRNewswire/ --

Added Experience in Clinical Development and Business Development to Support Company's Advancing Diagnostic Initiatives for Circulating Tumour DNA (ctDNA) 

Inivata Limited, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announces the appointment of Emma Green, Head of Clinical Development and Operations and John F. Beeler, Ph.D. Vice President of Business Development. Ms. Green will be responsible for clinical development initiatives at Inivata's laboratories in Cambridge, UK.  Dr. Beeler will focus on overseeing business development related activities including partnerships with diagnostic and biopharmaceutical companies and academic institutions internationally.

Ms. Green comes to Inivata from Cell Therapy Catapult where she was Head of Clinical Operations.  There she was responsible for the development of clinical trial designs, accountable for the delivery of clinical projects and worked to identify new opportunities as well as support existing collaborative projects.  Emma brings over 15 years of clinical research and development experience within small biotechnology and large pharmaceutical companies, including Pfizer, Aventis, Sosei UK, and Serentis Ltd.

Dr. Beeler brings to Inivata over 20 years of product and business development experience spanning the pharmaceutical and diagnostic industry including a history of having established partnerships with leading pharmaceutical companies.  Most recently he served as Director, Theranostics and Business Development at bioMerieux where he was responsible for executing companion diagnostic development and commercialization agreements with GlaxoSmithKline, Novartis and Gilead.  Dr. Beeler holds a Masters degree in biology from Villanova University and a Ph.D in pharmacology from the University of South Carolina School of Medicine.

Inivata CEO Michael Stocum said, "Our rapid growth and development, based on the recognition of our world-class technology, has created a need to bring further high calibre people into our management team.  In John and Emma we have attracted exceptionally talented and experienced individuals. I am confident they will both contribute greatly to the acceleration of Inivata's ctDNA collaborations, products, and business initiatives."   

About Inivata 

Inivata is a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. Inivata develops clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. Novel applications of ctDNA are enabled by Inivata's technology platform which includes its proprietary, enhanced TAm-Seq™ technology. For more information on Inivata, please visit http://www.inivata.com

Contacts:
Inivata
Liz Macfadyen ;  [email protected]

Citigate Dewe Rogerson
Chris Gardner/Sylvie Berrebi
Tel: +44 (0)207 638 9571
Email: [email protected]; [email protected]

SOURCE Inivata